|
1
|
Nordenstedt H, White DL and El-Serag HB:
The changing pattern of epidemiology in hepatocellular carcinoma.
Dig Liver Dis. 42(Suppl 3): S206–S214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thomas MB and Zhu AX: Hepatocellular
carcinoma: the need for progress. J Clin Oncol. 23:2892–2899. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J, Sala M and Llovet JM:
Chemoembolization for hepatocellular carcinoma. Gastroenterology.
127(5 Suppl 1): S179–S188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Szakács G, Paterson JK, Ludwig JA, et al:
Targeting multidrug resistance in cancer. Nat Rev Drug Discov.
5:219–234. 2006.
|
|
5
|
Zhang K, Mack P and Wong KP:
Glutathione-related mechanisms in cellular resistance to anticancer
drugs. Int J Oncol. 12:871–882. 1998.PubMed/NCBI
|
|
6
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: a link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gandellini P, Profumo V, Folini M and
Zaffaroni N: MicroRNAs as new therapeutic targets and tools in
cancer. Expert Opin Ther Targets. 15:265–279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Trang P, Weidhaas JB and Slack FJ:
MicroRNAs as potential cancer therapeutics. Oncogene. 27(Suppl 2):
S52–S57. 2008. View Article : Google Scholar
|
|
11
|
Zhou J and Wang W: Analysis of microRNA
expression profiling identifies microRNA-503 regulates metastatic
function in hepatocellular cancer cell. J Surg Oncol. 104:278–283.
2011. View Article : Google Scholar
|
|
12
|
Lu YC, Chen YJ, Wang HM, et al: Oncogenic
function and early detection potential of miRNA-10b in oral cancer
as identified by microRNA profiling. Cancer Prev Res (Phila).
5:665–674. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Özata DM, Caramuta S, Velázquez-Fernández
D, et al: The role of microRNA deregulation in the pathogenesis of
adrenocortical carcinoma. Endocr Relat Cancer. 18:643–655.
2011.PubMed/NCBI
|
|
14
|
Corbetta S, Vaira V, Guarnieri V, et al:
Differential expression of microRNAs in human parathyroid
carcinomas compared with normal parathyroid tissue. Endocr Relat
Cancer. 17:135–146. 2010. View Article : Google Scholar
|
|
15
|
Bruchard M and Ghiringhelli F: Tumor
microenvironment: regulatory cells and immunosuppressive cytokines.
Med Sci (Paris). 30:429–435. 2014.(In French).
|
|
16
|
Keppler D: Multidrug resistance proteins
(MRPs, ABCCs): importance for pathophysiology and drug therapy.
Drug Transporters: Handbook of Experimental Pharmacology. Fromm MF
and Kim RB: Springer; Heidelberg: pp. 299–323. 2011, View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu JJ, de la Garza J, Srinivasan SK, et
al: Important roles of ERCC1 in DNA repair and targeted therapy.
Cancer Drug Discovery and Development. Panasci L, Aloyz R and
Alaoui-Jamali M: Springer; New York, NY: pp. 129–142. 2013
|
|
18
|
Chen HH and Kuo MT: Role of glutathione in
the regulation of Cisplatin resistance in cancer chemotherapy. Met
Based Drugs. 2010:4309392010.PubMed/NCBI
|
|
19
|
Shanker M, Willcutts D, Roth JA and Ramesh
R: Drug resistance in lung cancer. Lung Cancer: Targets and
Therapy. 1:23–36. 2010.
|
|
20
|
Grise F, Sena S, Bidaud-Meynard A, et al:
Rnd3/RhoE is down-regulated in hepatocellular carcinoma and
controls cellular invasion. Hepatology. 55:1766–1775. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ryan BM, O’Donovan N and Duffy MJ:
Survivin: A new target for anti-cancer therapy. Cancer Treat Rev.
35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Altieri DC: Survivin and IAP proteins in
cell-death mechanisms. Biochem J. 430:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma J, Zhu W and Zhou Q: Expression and
significance of bag-1, bcl-2 in non-small cell lung cancer and the
correlation with multi-drug resistance. Zhongguo Fei Ai Za Zhi.
12:1089–1094. 2009.(In Chinese).
|
|
24
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qiu T, Zhou L, Wang T, Xu J, Wang J, et
al: miR-503 regulates the resistance of non-small cell lung cancer
cells to cisplatin by targeting Bcl-2. Int J Mol Med. 32:593–598.
2013.PubMed/NCBI
|
|
26
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sarkar S, Dey BK and Dutta A: miR-322/424
and -503 are induced during muscle differentiation and promote cell
cycle quiescence and differentiation by down-regulation of Cdc25A.
Mol Biol Cell. 21:2138–2149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
LoPiccolo J, Blumenthal GM, Bernstein WB
and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective
combinations and clinical considerations. Drug Resist Updat.
11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Budhu A and Wang XW: The role of cytokines
in hepatocellular carcinoma. J Leukoc Biol. 80:1197–1213. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gilmore TD: Introduction to NF-kappaB:
players, pathways, perspectives. Oncogene. 25:6680–6684. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shaulian E and Karin M: AP-1 in cell
proliferation and survival. Oncogene. 20:2390–2400. 2001.
View Article : Google Scholar : PubMed/NCBI
|
